type 1 diabetes Archives
Study sheds light on drug’s impact on diabetes progression
Mar. 23, 2023—A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.
Saunders receives diabetes research innovation award
Mar. 23, 2023—Vanderbilt's Diane Saunders, PhD, has been selected as a 2023 recipient of an Innovation Award by the Network of Pancreatic Donors with Diabetes.
Family’s participation key to advancing diabetes research
Mar. 9, 2023—A study of one family from Alabama has led Vanderbilt researchers to discover that insulin deficiency, independent of the autoimmunity associated with Type 1 diabetes, is the principal factor leading to a markedly smaller pancreas.
Vanderbilt mourns loss of former Rheumatology director Thomas
Nov. 21, 2022—James Ward “Tom” Thomas II, MD, former director of Vanderbilt’s Division of Rheumatology and Immunology, died Nov. 16 following a battle with cancer. He was 74.
Trial participant steps up to help advance diabetes research
Sep. 1, 2022—Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.
International gathering scrutinizes immune response, beta cell biology in Type 1 diabetes
Nov. 11, 2021— by Jill Clendening Nearly 400 investigators and scientific trainees hailing from 25 different countries recently gathered virtually, across continents and time zones, to share their latest research related to the immunology of Type 1 diabetes during the 18th Immunology of Diabetes Society (IDS) Congress, co-hosted by Vanderbilt University Medical Center and the University of...
Aug. 24, 2021—Vanderbilt researchers have developed a high-throughput screening method to identify and characterize antigen-specific B cells — potential biomarkers for autoimmune disease and targets for new treatments.
Gene expression in diabetic nephropathy
Aug. 5, 2021—Vanderbilt researchers are looking to mRNA populations in podocytes — kidney cells that help filter blood — to help identify potential targets for treating diabetic kidney disease.
Targeting glucagon action in diabetes
Mar. 4, 2021—Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.
Discovery may point to better treatments for Type 1 diabetes
Aug. 22, 2019—Researchers have made a paradigm-shifting discovery that could lead to new treatments, better health and longer life for patients with Type 1 diabetes.
Study drug delays type 1 diabetes in high risk children and adults
Jun. 9, 2019—Drug delays onset of type 1 diabetes by two years
Healthy antibodies reverse diabetes
Sep. 13, 2018—Vanderbilt researchers have discovered that IgM-type antibodies appear to play a protective role to prevent the development of type 1 diabetes — and that purified IgM antibodies can reverse the disease.